| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Pseudolaric Acid C targets fungal cells, exhibiting antifungal activity against various fungi including Candida albicans. It also has anticancer and anti-inflammatory activities. Its mechanism of action involves antifungal effects through disruption of fungal cell function. Its anticancer effects are likely mediated through inhibition of cancer cell proliferation. Its anti-inflammatory effects are mediated through reduction of inflammatory mediator production.
|
|---|---|
| ln Vitro |
In vitro, Pseudolaric Acid C shows weak antifungal activity against Candida albicans. It exhibits antifungal, anticancer, and anti-inflammatory properties. It shows potent antifungal effects against various fungi. It has potential as an anticancer agent against certain cancer cells. It displays anti-inflammatory activity by reducing the production of inflammatory mediators. Quantitative IC50 values for its antifungal or anticancer activities are not detailed in the publicly available sources.
|
| ln Vivo |
In vivo activity data for Pseudolaric Acid C is limited in publicly available literature. As a compound with antifungal, anticancer, and anti-inflammatory properties in vitro, it is hypothesized to exhibit similar effects in animal models. However, specific in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been detailed in the available sources. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For in vitro cell-free assays, the antifungal activity of Pseudolaric Acid C can be assessed using standard antifungal susceptibility testing. The compound is tested against various fungal strains (e.g., Candida albicans) using broth microdilution methods to determine the minimum inhibitory concentration (MIC). Its anti-inflammatory activity can be assessed by measuring its ability to inhibit the production of inflammatory mediators in cell-free enzyme assays. Its anticancer activity can be assessed using enzyme inhibition assays targeting cancer-related pathways.
|
| Cell Assay |
For in vitro cellular assays, the antifungal activity of Pseudolaric Acid C is assessed in fungal cultures using broth microdilution or agar dilution methods to determine MIC values. Its anticancer activity is assessed in cancer cell lines by measuring cell viability using MTT or SRB assays. Its anti-inflammatory activity is assessed in immune cells by measuring the production of inflammatory mediators.
|
| Animal Protocol |
For in vivo studies, Pseudolaric Acid C could be administered orally or intraperitoneally in animal models of fungal infection, cancer, or inflammation. In antifungal studies, endpoints include reduction in fungal load and survival. In cancer models, endpoints include tumor volume measurement and survival analysis. In inflammation models, endpoints include inflammatory biomarker analysis and tissue histopathology.
|
| ADME/Pharmacokinetics |
Pseudolaric Acid C (CAS 82601-41-0) has a molecular formula of C21H26O7 and a molecular weight of 390.43 g/mol. It is also known as Deacetylpseudolaric acid B. Appearance: white crystalline powder. Solubility: soluble in methanol, ethanol, DMSO, and other organic solvents. Storage: store under recommended conditions. Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural diterpenoid from Pseudolarix kaempferi, it is generally considered to have low toxicity, but standard toxicological studies would be required for drug development. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that observed effects are not due to a general reduction in cell viability.
|
| References | |
| Additional Infomation |
According to reports, (2E,4E)-5-[(1R,7S,8R,9R)-7-hydroxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tetadeca-3-en-9-yl]-2-methylpent-2,4-dienoic acid has been found in Pseudolarix amabilis and Larix kaempferi, and relevant data are available.
Pseudolaric Acid C is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying antifungal, anticancer, and anti-inflammatory activities. Its mechanism of action involves antifungal effects, anticancer effects through inhibition of cancer cell proliferation, and anti-inflammatory effects through reduction of inflammatory mediator production. It is isolated from the root bark of Pseudolarix kaempferi. No clinical trials have been reported. |
| Molecular Formula |
C21H26O7
|
|---|---|
| Molecular Weight |
390.4269
|
| Exact Mass |
390.167
|
| CAS # |
82601-41-0
|
| PubChem CID |
6440704
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
613.2±55.0 °C at 760 mmHg
|
| Flash Point |
214.8±25.0 °C
|
| Vapour Pressure |
0.0±4.0 mmHg at 25°C
|
| Index of Refraction |
1.585
|
| LogP |
1.92
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
808
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C/C(=C\C=C\[C@@]1([C@@H]2CC[C@@]3([C@@]2(CCC(=CC3)C(=O)OC)O)C(=O)O1)C)/C(=O)O
|
| InChi Key |
RBXVTEUAOTYIME-GPGKBOPFSA-N
|
| InChi Code |
InChI=1S/C21H26O7/c1-13(16(22)23)5-4-9-19(2)15-8-11-20(18(25)28-19)10-6-14(17(24)27-3)7-12-21(15,20)26/h4-6,9,15,26H,7-8,10-12H2,1-3H3,(H,22,23)/b9-4+,13-5+/t15-,19+,20+,21-/m0/s1
|
| Chemical Name |
(2E,4E)-5-[(1R,7S,8R,9R)-7-hydroxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~256.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.40 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5613 mL | 12.8064 mL | 25.6128 mL | |
| 5 mM | 0.5123 mL | 2.5613 mL | 5.1226 mL | |
| 10 mM | 0.2561 mL | 1.2806 mL | 2.5613 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
